

PRODUCT MONOGRAPH

INCLUDING PATIENT MEDICATION INFORMATION

PrKuvan[®]

(sapropterin dihydrochloride)

100 mg Tablets

Alimentary Tract and Metabolism Products

BioMarin Pharmaceutical (Canada) Inc.
Toronto, ON
Canada M5H 3C2
www.bmrn.com

Date of Revision:
December 4, 2014

Submission Control No: 128151

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	3
WARNINGS AND PRECAUTIONS.....	3
ADVERSE REACTIONS.....	6
DRUG INTERACTIONS	11
DOSAGE AND ADMINISTRATION	12
OVERDOSAGE	13
ACTION AND CLINICAL PHARMACOLOGY	14
STORAGE AND STABILITY.....	16
DOSAGE FORMS, COMPOSITION AND PACKAGING	16
PART II: SCIENTIFIC INFORMATION	17
PHARMACEUTICAL INFORMATION.....	17
CLINICAL TRIALS.....	18
DETAILED PHARMACOLOGY	21
TOXICOLOGY	22
REFERENCES	24
PART III: PATIENT MEDICATION INFORMATION	25

PrKuvan[®]
(sapropterin dihydrochloride) Tablets

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Tablet 100 mg	<i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i>

INDICATIONS AND CLINICAL USE

Kuvan[®] (sapropterin dihydrochloride) is indicated in conjunction with a Phe-restricted diet to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH₄)-responsive Phenylketonuria (PKU).

Geriatrics (65 years and older): Clinical studies of Kuvan in patients with PKU did not include patients aged 65 years and older. It is not known whether these patients respond differently to Kuvan than younger patients.

Pediatrics (less than 16 years of age): Pediatric patients with PKU, ages 4 to 16 years, have been treated with Kuvan in clinical studies [see CLINICAL TRIALS]. The safety and efficacy of Kuvan in pediatric patients less than 4 years of age have not been established in clinical trials. [See WARNINGS AND PRECAUTIONS, Special Populations].

CONTRAINDICATIONS

Patients who are hypersensitive to this drug or to any ingredient in the formulation, or to any component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the product monograph.

WARNINGS AND PRECAUTIONS

General

Monitor Blood Phe Levels During Treatment

Treatment with Kuvan should be directed by physicians knowledgeable in the management of PKU. Prolonged elevations in blood Phe levels in patients with PKU can result in severe neurologic damage, including severe mental retardation, microcephaly, delayed speech, seizures, and behavioral abnormalities. This may occur even if patients are taking Kuvan but not

adequately controlling their blood Phe levels within the recommended target range. Neurocognitive outcomes with Kuvan treatment have not been established in long term clinical studies. Conversely, prolonged levels of blood Phe that are too low have been associated with catabolism and protein breakdown. Active management of dietary Phe intake while taking Kuvan is required to ensure adequate Phe control and nutritional balance.

Identify Non-Responders to Kuvan Treatment

Not all patients with PKU respond to treatment with Kuvan. In clinical trials, approximately 20% to 56% of PKU patients responded to treatment with Kuvan [see CLINICAL TRIALS].

Response to treatment cannot be pre-determined by laboratory testing (e.g., genetic testing), and should only be determined by a therapeutic trial of Kuvan [see DOSAGE AND ADMINISTRATION].

Treat All Patients With a Phe-restricted Diet

Patients with PKU who are being treated with Kuvan should also be treated with a Phe-restricted diet. The initiation of Kuvan therapy does not eliminate the need for appropriate monitoring by trained professionals to assure that blood Phe control is maintained in the context of ongoing dietary management.

Cardiovascular

Use with Drugs Known to Affect Nitric Oxide-Mediated Vasorelaxation

Caution should be used with the administration of Kuvan to patients who are receiving drugs that affect nitric oxide mediated vasorelaxation (e.g., PDE-5 inhibitors such as sildenafil, vardenafil, or tadalafil), because both sapropterin dihydrochloride and PDE-5 inhibitors may induce vasorelaxation. The possible additive effect of co-administering sapropterin and PDE-5 inhibitors potentially could lead to a reduction in blood pressure; however, the combined use of these medications has not been evaluated in humans.

Endocrine and Metabolism

Use with Medications Known to Inhibit Folate Metabolism

Drugs known to affect folate metabolism (e.g., methotrexate) and their derivatives should be used with caution while taking Kuvan because these drugs can decrease BH4 levels by inhibiting the enzyme dihydropteridine reductase (DHPR).

Gastrointestinal

Gastritis

During clinical studies, gastritis was reported as a serious adverse reaction. Monitor patients for signs and symptoms of gastritis (see ADVERSE REACTIONS).

Hepatic

Use with Caution in Patients with Hepatic Impairment

Patients with liver impairment have not been evaluated in clinical trials with Kuvan. Patients who have liver impairment should be carefully monitored when receiving Kuvan because hepatic damage has been associated with impaired Phe metabolism.

Immune

Hypersensitivity Reactions Including Anaphylaxis

Kuvan is contraindicated in patients with a history of anaphylaxis to Kuvan (see CONTRAINDICATIONS). Hypersensitivity reactions, including anaphylaxis and rash, have occurred [see ADVERSE REACTIONS]. Signs of anaphylaxis include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. Discontinue treatment with Kuvan in patients who experience anaphylaxis and initiate appropriate medical treatment. Continue dietary Phe restrictions in patients who experience anaphylaxis.

Neurologic

Use With Caution When Co-administering Kuvan and Levodopa

Caution should be used with the administration of Kuvan to patients who are receiving levodopa. In a 10 year post-marketing safety surveillance program for a non-PKU indication using another formulation of the same active ingredient (sapropterin), 3 patients with underlying neurologic disorders experienced convulsions, exacerbation of convulsions, over-stimulation, or irritability during co-administration of levodopa and sapropterin.

Hyperactivity

In the post-marketing safety surveillance program for PKU, some patients experienced hyperactivity with administration of Kuvan. Monitor patients for hyperactivity [see OVERDOSAGE].

Renal

Patients with renal impairment have not been evaluated in clinical trials. Patients who have renal impairment should be carefully monitored when receiving Kuvan.

Special Populations

Pregnant Women: Reproduction studies have been performed in rats and rabbits up to 400 mg/kg/day and 600 mg/kg/day, respectively (about 3 times in rats and 10 times in rabbits the human clinical dose of 20 mg/kg/day, based on body surface area).

No evidence of teratogenic effects has been observed in either species; however, in rabbits there was an increase in the incidence, not statistically significant, of holoprosencephaly at the 600 mg/kg/day dose. Placental migration of sapropterin dihydrochloride to the fetuses was not seen in rats dosed orally at 10 mg/kg/day during pregnancy.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the expected benefits outweigh the risks. Elevated Phe levels in pregnant women are teratogenic and can cause significant congenital brain and cardiac damage in babies of PKU-affected mothers, known as Maternal PKU Syndrome. Uncontrolled Phe levels (above 600 $\mu\text{mol/L}$) are associated with a very high incidence of neurological, cardiac, facial dysmorphism, and growth abnormalities in babies of PKU-affected mothers.

Labor and Delivery: The effects of Kuvan on labor and delivery in pregnant women have not been studied. Kuvan use during labor and delivery is not recommended.

Nursing Women: Sapropterin dihydrochloride is excreted in the milk of intravenously, but not orally, treated lactating rats. It is not known whether sapropterin is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from sapropterin and because of the potential for tumorigenicity shown for sapropterin in the rat carcinogenicity study, Kuvan should not be administered during lactation.

Pediatrics (less than 16 years of age):

Pediatric patients with PKU, ages 4 to 16 years, have been treated with Kuvan in clinical studies [see CLINICAL TRIALS]. The safety and efficacy of Kuvan in pediatric patients less than 4 years of age have not been established in clinical trials. Frequent blood monitoring is recommended in the pediatric population to ensure adequate blood Phe level control.

Geriatrics (65 years and older): Clinical studies of Kuvan in patients with PKU did not include patients aged 65 years and older. It is not known whether these patients respond differently to Kuvan than younger patients.

Monitoring and Laboratory Tests

Patients being treated with Kuvan should have frequent blood Phe level measurements and dietary guidance from a dietitian to ensure maintenance of blood Phe levels in the desirable range [1].

ADVERSE REACTIONS

Adverse Drug Reaction Overview

In clinical trials, a total of 579 PKU patients were administered Kuvan in doses ranging from 5 to 20 mg/kg/day for lengths of treatment ranging from 1 to 30 weeks. Patients were aged 4 to 49 years old. The patient population was nearly evenly distributed in gender, and approximately 95% of patients were Caucasian.

No deaths were reported. 310 (54%) of the Kuvan-treated patients reported at least one adverse event (AE). 5 patients (1%) reported the following serious adverse events (SAEs) (regardless of relationship to treatment): appendicitis, urinary tract infection, gastroesophageal reflux disease, spinal cord injury, tibia fracture, streptococcal infection, and testicular carcinoma. The most commonly reported AEs (in $\geq 4\%$ of the Kuvan-treated patients) were: headache (13%), diarrhoea (6%), abdominal pain (6%), upper respiratory tract infection (5%), pharyngolaryngeal pain (5%), vomiting (4%), and nausea (4%). No Kuvan-treated patients discontinued treatment due to an AE during the clinical trials.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information

from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In two double-blind, placebo-controlled trials, 74 patients were treated with Kuvan while 59 patients were treated with placebo. The data described below reflect exposure of 74 PKU patients to Kuvan at doses of 10 to 20 mg/kg/day for 6 to 10 weeks. The overall incidence of adverse events in patients receiving Kuvan (64%) was similar to that reported with patients receiving placebo (71%).

Table 1 enumerates treatment-emergent adverse events that occurred in more than 1 patient ($\geq 2\%$) treated with Kuvan in the double-blind, placebo-controlled clinical studies described above.

Table 1: Summary of Adverse Events by Preferred Term Occurring in $\geq 2\%$ of Patients in Controlled Clinical Studies With Kuvan

MedDRA Preferred Term	Placebo (n=59)	Kuvan (n=74)
No. of Patients Reporting at Least One AE	42 (71.2%)	47 (63.5%)
Headache	8 (13.6%)	11 (14.9%)
Upper respiratory tract infection	14 (23.7%)	9 (12.2%)
Rhinorrhoea	0	8 (10.8%)
Pharyngolaryngeal pain	1 (1.7%)	7 (9.5%)
Diarrhoea	3 (5.1%)	6 (8.1%)
Vomiting	4 (6.8%)	6 (8.1%)
Cough	3 (5.1%)	5 (6.8%)
Pyrexia	4 (6.8%)	5 (6.8%)
Abdominal pain	5 (8.5%)	4 (5.4%)
Contusion	1 (1.7%)	4 (5.4%)
Rash	4 (6.8%)	4 (5.4%)
Nasal congestion	0	3 (4.1%)
Back pain	3 (5.1%)	2 (2.7%)
Decreased appetite	0	2 (2.7%)
Erythema	0	2 (2.7%)
Excoriation	0	2 (2.7%)
Fatigue	3 (5.1%)	2 (2.7%)
Infection	0	2 (2.7%)
Lymphadenopathy	0	2 (2.7%)
Otitis externa	0	2 (2.7%)
Pharyngitis	1 (1.7%)	2 (2.7%)
Streptococcal infection	3 (5.1%)	2 (2.7%)
Toothache	0	2 (2.7%)
Urinary tract infection	0	2 (2.7%)

In open-label, uncontrolled clinical trials in which all patients received Kuvan in doses of 5 to 20 mg/kg/day, AEs were similar in type and frequency to those reported in the double-blind, placebo-controlled clinical trials.

In an additional open-label extension study of Kuvan, 111 PKU patients were treated within a range of 5 mg/kg/day to 20 mg/kg/day to control blood Phe concentrations for an additional 18 months beyond their exposure in previous clinical studies. No deaths were reported. Four patients reported SAEs (3 unrelated and 1 possibly related case of gastroesophageal reflux disease). Two patients withdrew from the study due to an AE (difficulty concentrating and intermittent diarrhoea). Clinical laboratory results, vital sign measurements, and physical examinations did not reveal any clinically significant AE signals resulting from Kuvan treatment.

Less Common Clinical Trial Adverse Events (<2%)

Blood and Lymphatic System: lymphadenopathy, neutropenia

Cardiac Disorders: cardiac murmur, heart rate increased

Congenital, Familial and Genetic Disorders: ichthyosis

Eye Disorders: eye pain, lacrimation increased

Gastrointestinal Disorders: abdominal distension, abdominal pain lower, abdominal pain upper, abdominal tenderness, abnormal faeces, constipation, dry mouth, dyspepsia, flatulence, frequent bowel movements, gingival bleeding, gingival pain, haematochezia, haemorrhoids, retching, stomach discomfort, tongue spasm, gastroesophageal reflux disease (GERD), epigastric ulcer

General Disorders and Administration Site Conditions: asthenia, chest discomfort, chills, energy increased, feeling hot, influenza like illness, irritability, malaise, oedema peripheral, pyrexia, suprapubic pain, thirst

Infections and Infestations: ear infection, eye infection, herpes zoster, hordeolum, influenza, lower respiratory tract infection, nasopharyngitis, pharyngitis, sinusitis, streptococcal infection, tooth abscess, upper respiratory tract infection, urinary tract infection

Injury, Poisoning and Procedural Complications: contusion, excoriation

Investigations: alanine aminotransferase increased, aspartate aminotransferase increased, blood amino acid level increased, blood bilirubin increased, blood cholesterol increased, blood lactate dehydrogenase increased, blood uric acid increased, eosinophil count increased, gamma-glutamyltransferase increased, glucose urine present, neutrophil count decreased, platelet count decreased, protein urine present, urine colour abnormal, white blood cell count decreased

Metabolism and Nutrition Disorders: anorexia, decreased appetite, polydipsia

Musculoskeletal and Connective Tissue Disorders: arthralgia, back pain, muscle fatigue, myalgia, neck pain, pain in jaw

Nervous System Disorders: cluster headache, disturbance in attention, dizziness, dysgeusia, dysgraphia, hyperreflexia, hypersomnia, lethargy, migraine, psychomotor hyperactivity, sinus headache, somnolence, syncope, tremor, convulsions

Psychiatric Disorders: agitation, confusional state, distractibility, emotional disorder, insomnia, libido increased, mood altered, panic attack, paranoia, sleep disorder

Renal and Urinary Disorders: micturition urgency, pollakiuria, polyuria, nephrolithiasis

Reproductive System and Breast Disorders: menstrual disorder, vaginal haemorrhage

Respiratory, Thoracic and Mediastinal Disorders: asthma, cough, epistaxis, nasal congestion, respiratory tract congestion, rhinorrhoea, sneezing, throat irritation

Skin and Subcutaneous Tissue Disorders: dermal cyst, dermatitis allergic, dry skin, erythema, erythema multiforme, rash, rash erythematous, rash maculo-papular, rash pruritic, skin odour abnormal

Vascular Disorders: hot flush, peripheral coldness

Abnormal Hematologic and Clinical Chemistry Findings

Table 2: Clinically Significant Abnormal Changes in Hematological Test Findings Reported in Kuvan-Treated Patients

Parameter Notable Criteria (Reference Ranges)	Controlled Studies		All Kuvan-Treated (n=579)
	Placebo (n=59)	Kuvan (n=74)	
No. of Patients with Lab Test Done	59	74	578
Hematocrit			
> 20% increase from baseline and ≥ 1.3 x ULN (34.9 ~ 44.5%)	-	-	1 (0.2%)
Leukocytes			
> 30% decrease from baseline and ≤ 0.6 x LLN (3.4 ~ 10.5 x 10 ⁹ /L)	-	-	1 (0.2%)
> 25% increase from baseline and > 1.5 x ULN (3.4 ~ 10.5 x 10 ⁹ /L)	-	-	1 (0.2%)
Eosinophils (%)			
> 100% increase from baseline and > 3 x ULN (1 ~ 4%)	-	-	1 (0.2%)
Lymphocytes (%)			
> 10% decrease from baseline and < 0.2 x LLN (17 ~ 42%)	-	-	1 (0.2%)
Neutrophils (count)			
> 5% decrease from baseline and < 0.5 x LLN (1.5 ~ 8 x 10 ⁹ /L)	2 (3.4%)	2 (2.7%)	2 (0.3%)
> 1.6 x ULN (1.5 ~ 8 x 10 ⁹ /L)	-	-	8 (1.4%)
Platelets			
Any decrease from baseline and < 0.6 x LLN (150 ~ 450 x 10 ⁹ /L)	-	-	4 (0.7%)
≥ 100% increase from baseline and > 2 x ULN (150 ~ 450 x 10 ⁹ /L)	1 (1.7%)	-	-

LLN= Lower limit of normal, ULN= Upper limit of normal

Table 3: Clinically Significant Abnormal Changes in Chemistry Test Findings Reported in Kuvan-Treated Patients

Parameter Notable Criteria (Reference Ranges)	Controlled Studies		All Kuvan-Treated (n=579)
	Placebo (n=59)	Kuvan (n=74)	
No. of Patients with Lab Test Done	59	74	578
Alkaline phosphatase			
Any decrease from baseline and < 0.4 x LLN (138 ~ 511 U/L)	-	-	1 (0.2%)
ALT			
> 20% increase from baseline and > 3 x ULN (0 ~ 45 U/L)	-	-	6 (1.0%)
AST			
> 50% increase from baseline and > 2 x ULN (0 ~ 40 U/L)	1 (1.7%)	-	3 (0.5%)
GGT			
> 10% increase from baseline and > 3 x ULN (6 ~ 37 U/L)	-	1 (1.4%)	3 (0.5%)
Glucose			
< 0.5 x LLN (70 ~ 100 mg/dL)	-	-	1 (0.2%)
LDH			
< 0.1 x LLN (145 ~ 345 U/L)	-	-	1 (0.2%)
Potassium			
> 1.2 x ULN (3.6 ~ 5 mmol/L)	-	1 (1.4%)	3 (0.5%)
Total Bilirubin			
> 5% increase from baseline and > 2.5 x ULN (0.1 ~ 1 mg/dL)	-	-	2 (0.3%)
Total Cholesterol			
> 10% increase from baseline and > 1.25 x ULN (0 ~ 239 mg/dL)	-	-	2 (0.3%)

LLN= Lower limit of normal, ULN= Upper limit of normal

Post Marketing Adverse Drug Reactions

The following adverse reactions have been identified during post-approval use of Kuvan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.

Eye disorders: eyelid oedema

Gastrointestinal disorders: gastritis, oesophageal pain, oesophageal disorder, dyspepsia, abdominal pain, retching, nausea, vomiting, GERD, and epigastric ulcer

General disorders and administration site conditions: oedema peripheral

Immune system disorders: hypersensitivity, anaphylaxis

Infections and infestations: pharyngitis

Nervous System Disorders: hyperactivity [see OVERDOSAGE], convulsions

Respiratory, thoracic and mediastinal disorders: cough, dyspnoea, oropharyngeal pain, throat tightness

Renal: nephrolithiasis

Skin and subcutaneous tissue disorders: urticaria, rash

Vascular disorders: pallor

DRUG INTERACTIONS

Overview

Sapropterin dihydrochloride does not induce cytochrome P450 activity nor is it metabolized through the cytochrome P450 metabolic pathway.

Drug-Drug Interactions

No drug interaction studies have been performed for Kuvan.

Table 4: Potential Drug-Drug Interactions

Co-administered Drug	Reference	Effect	Clinical comment
Drugs that affect nitric-oxide mediated vasorelaxation (e.g., PDE-5 inhibitors such as sildenafil, vardenafil, or tadalafil)	Theoretical	Hypotension	Caution should be used with the administration of Kuvan to patients who are receiving drugs that affect nitric oxide mediated vasorelaxation The combined use of these medications has not been evaluated in humans. (see WARNINGS AND PRECUATIONS)
Drugs known to affect folate metabolism (e.g., methotrexate) and their derivatives	Theoretical	Decrease of BH4 levels by inhibiting the enzyme dihydropteridine reductase (DHPR)	Caution should be used with the administration of Kuvan to patients who are receiving drugs that are known to affect folate metabolism. (see WARNINGS AND PRECUATIONS)
Levodopa	Case Study (post-marketing)	Convulsions, exacerbation of convulsions, over-stimulation, or irritability	Caution should be used with the administration of Kuvan to patients who are receiving levodopa. (see WARNINGS AND PRECUATIONS)

DOSAGE AND ADMINISTRATION**Recommended Dose and Dosage Adjustment**

The recommended starting dose of Kuvan is 10 mg/kg/day daily.

Response to therapy is determined by change in blood Phe following treatment with Kuvan at 10 mg/kg/day for a period of up to 1 month. Blood Phe levels should be checked after 1 week of Kuvan treatment and periodically for up to a month. If blood Phe does not decrease from baseline at 10 mg/kg/day, the dose may be increased weekly to a maximum of 20 mg/kg/day, with frequent monitoring of blood Phe levels over a one month period. Patients whose blood Phe does not decrease after 1 month of treatment at 20 mg/kg/day are considered non-responders, and treatment with Kuvan should be discontinued in these patients. Once responsiveness to Kuvan has been established, the dosage may be adjusted within the range of 5 to 20 mg/kg/day according to response to therapy. Doses of Kuvan above 20 mg/kg/day have not been evaluated for efficacy and safety in clinical trials.

Monitoring

As recommended for clinical management of PKU, blood Phe levels in patients receiving Kuvan should be tested one or two weeks after each dose adjustment and monitored frequently thereafter [1]. Patients treated with Kuvan must continue on a restricted phenylalanine diet.

Missed Dose

A missed dose should be taken as soon as possible, but 2 doses should not be taken on the same day.

Administration

For PKU, Kuvan should be administered orally with a meal to increase absorption, and preferably at the same time each day. When Kuvan is taken with a high fat, high calorie meal, the absorption of the drug increases by 30 – 80% [see Pharmacokinetics].

Kuvan tablets can be swallowed either as whole tablets or dissolved in 120 – 240 mL (4 to 8 oz) of water or apple juice and taken within 15 minutes of dissolution. To make the tablets dissolve faster, tablets may be stirred or crushed. The tablets may not dissolve completely and patients may see small pieces floating on top of the water or apple juice. If after drinking the medicine, patients still see pieces of the tablet in the container, more water or apple juice can be added to make sure all of the medicine is consumed.

Kuvan tablets may also be crushed and then mixed in a small amount of soft foods such as apple sauce or pudding and consumed within 15 minutes of mixing.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Two unintentional overdoses with Kuvan have been reported. In one of the reported overdoses with Kuvan, a subject participating in a 26-week study received a single dose of 4500 mg (36 mg/kg) instead of 2600 mg (20 mg/kg) in Week 16 of the study. The subject reported mild headache and mild dizziness after taking the dose; both symptoms resolved within one hour with no treatment intervention. Results from liver function laboratory tests obtained immediately following the event were within normal limits. The subject suspended therapy for 24 hours and then restarted Kuvan with no reports of abnormal signs or symptoms. In postmarketing, one pediatric patient received Kuvan doses of 45 mg/kg per day instead of 20 mg/kg per day. The patient reported hyperactivity that began at an unspecified time after overdose and resolved after the Kuvan dose was reduced to 20 mg/kg per day.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Kuvan is a synthetic formulation of BH₄, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is absent or deficient. Treatment with BH₄ can activate residual PAH enzyme, improve the oxidative metabolism of Phe, and decrease Phe levels in some patients.

Pharmacodynamics

In PKU patients who are responsive to BH₄ treatment, blood Phe levels decrease within 24 hours after a single administration of sapropterin dihydrochloride, although maximal effect on Phe level may take a month or longer, depending on the patient [2]. A single daily dose of Kuvan is adequate to maintain stable blood Phe levels over a 24-hour period. Twelve BH₄ responsive patients reduced their blood Phe levels within the range of 516 to 986 μmol/L (mean 747 ± 152.6 μmol/L), and maintained their blood Phe levels over a 24-hour period following a daily morning dose of 10 mg/kg/day. The blood Phe level remained stable during a 24-hour observation period. No substantial increases in blood Phe levels were observed following food intake throughout the 24-hour period.

Effects of Kuvan on the QTc interval

A randomised, placebo- and active-controlled, 4-period crossover ECG assessment study was performed in 56 healthy adult subjects. The subjects received single 20 mg/kg and 100 mg/kg oral doses of sapropterin. At the therapeutic 20 mg/kg dose, sapropterin was associated with statistically significant QTc (QT/RR^{0.37}) shortening at 3 and 6 hours post-dosing, with a maximum mean difference from placebo of -2.6 (90% CI -4.6, -0.6) ms at 3 h post-dosing. At the suprathreshold 100 mg/kg dose, statistically significant QTc shortening was observed from 2 to 6 hours, inclusive, and at 10 h with a maximum mean difference from placebo of -8.2 (90% CI -10.4, -6.0) ms at 4.5 h post-dosing.

At the therapeutic 20 mg/kg dose, sapropterin had no effect on heart rate. At the suprathreshold 100 mg/kg dose, heart rate was significantly increased from 3 to 4.5 h post-dosing, with a maximum mean difference from placebo of 4.0 (90% CI 2.8, 5.2) bpm at 3.5 h post-dosing. The clinical relevance of the data has not been established.

Pharmacokinetics

Studies in healthy volunteers have shown comparable absorption of sapropterin dihydrochloride when tablets are dissolved in water or orange juice and taken under fasted conditions. Administration of dissolved tablets after a high-fat/high-calorie meal resulted in mean increases in C_{max} of 84% and AUC of 87% (dissolved in water). However, there was extensive variability in individual subject values for C_{max} and AUC across the different modes of administration and meal conditions. There is substantial overlap among the different ways of administering Kuvan (intact tablets, dissolved in water, dissolved in orange juice, fasted and fed), results which indicate that the rate and extent of exposure are comparable.

Although there is a trend toward an increase in exposure when Kuvan is administered with a high fat, high calorie meal as noted above, there is substantial overlap in the individual subject values for C_{max} and AUC_{0-t}. Taking into account the safety profile of Kuvan over doses ranging from 5-

20 mg/kg/day any increased exposure due to administration with food does not appear to be of clinical significance.

In the clinical trials of Kuvan, drug was administered in the morning as a dissolved tablet before breakfast.

A population pharmacokinetic analysis of sapropterin that included patients between 8 and 49 years of age showed no effect of age on sapropterin dihydrochloride pharmacokinetics. There was an effect of weight on sapropterin dihydrochloride pharmacokinetics thereby supporting weight-based dosing. The mean terminal elimination half-life of Kuvan was approximately 6.7 hours (range 3.9 to 17 hr) supporting once daily dosing [3]. Pharmacokinetics in patients < 8 years and > 49 years of age have not been studied.

Table 5: Summary of Kuvan’s Pharmacokinetic Parameters in healthy subjects when administered under fed conditions either dissolved in water or swallowed intact

	C_{max} (ng/mL)	t_½ (hr)	T_{max} (hr) (range)	AUC_{0-t}
Study PKU-005 100 mg Tablet orally 10 mg/kg Fed condition Dissolved in water	99.4 ± 38.8	2.97 ± 0.84	5 (3-6)	557 ± 169
Study PKU-009 100 mg Tablet orally 10 mg/kg Fed condition Tablet swallowed intact	121 ± 33.6	4.28 ± 2.79	4.0 (1-5)	709 ± 221
Study PKU-013 100 mg Tablet orally Fed condition Tablet swallowed intact	105 ± 32.1	2.80 ± 1.05	4.5 (2-5)	752 ± 307

In Study PKU-013, healthy adults with 10 mg/kg of Kuvan demonstrated the absorption via intact tablet administration was 40% greater than via dissolved tablet administration under fasted conditions based on AUC_{0-t}. The administration of intact tablets under fed conditions resulted in an approximately 43% increase in the extent of absorption compared to fasted conditions based on AUC_{0-t}.

Special Populations and Conditions

Pediatrics: A population pharmacokinetic analysis of sapropterin in patients 8 years and older showed no effect of age on sapropterin dihydrochloride pharmacokinetics.

STORAGE AND STABILITY

Store at 20°C - 25°C; excursions allowed between 15°C - 30°C [See USP Controlled Room Temperature]. Keep container tightly closed. Protect from moisture.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Kuvan[®] Tablets are unscored, uncoated, immediate-release tablets for oral use. Each tablet contains 100 mg of sapropterin dihydrochloride (equivalent to 76.8 mg of sapropterin base). Tablets are round, off-white to light yellow, mottled, and debossed with '177'.

Each tablet contains the following inactive ingredients: ascorbic acid (USP), crospovidone (NF), dibasic calcium phosphate (USP), D-mannitol (USP), riboflavin (USP), and sodium stearyl fumarate (NF).


Kuvan is supplied in high-density polyethylene bottles, sealed with aluminized film, and closed with child resistant caps. Each bottle contains 120 tablets, a silica gel desiccant cartridge, and a pharmaceutical-grade polyester coil.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	sapropterin dihydrochloride
Chemical name:	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl] 5,6,7,8-tetrahydro-4(1H)-pteridinone Dihydrochloride
Molecular formula and molecular mass:	$C_9H_{15}N_5O_3 \cdot 2HCl$ 314.17
Structural formula:	



Physicochemical properties:

Sapropterin dihydrochloride, the active pharmaceutical ingredient in Kuvan, is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH₄). Sapropterin dihydrochloride is an off-white to light yellow crystals or crystalline powder. Sapropterin dihydrochloride is very soluble in water, is only slightly soluble in methanol and ethanol, and is practically insoluble in other organic solvents. It melts (with decomposition) at 231-241 °C. Several polymorphic forms have been identified; however, the drug substance is manufactured as a single, stable anhydrous polymorph.

CLINICAL TRIALS

PKU Study Demographics and Trial Design

Table 6: Summary of Patient Demographics and Trial Design in Controlled PKU Studies

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n=number)	Mean age (Range)	Gender
PKU-003	Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled	Kuvan at 10 mg/kg or placebo, orally, once daily for 6 weeks	PKU patients (n = 88) 41 on Kuvan 47 on placebo	20 years (8 to 49 years)	51 M/37 F
PKU-006	Multicenter, Randomized, Double-blind, Placebo-controlled	Kuvan at 20 mg/kg or placebo, orally, once daily for 6 weeks	PKU patients (n = 45) 33 on Kuvan 12 on placebo	8 years (4 to 12 years)	26 M/19 F

Table 7: Summary of Patient Demographics and Trial Design in Open-label PKU Studies

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n=number)	Mean age (Range)	Gender
PKU-001	Multicenter, Open-label	Kuvan at 10 mg/kg, orally, once daily for 8 days	PKU patients (n = 489)	22 years (8 to 48 years)	235 M/ 254 F
PKU-004	Multicenter, Open-label	Kuvan at 5, 10 or 20 mg/kg, orally, once daily for 22 weeks	PKU patients (n = 80)	20 years (8 to 49 years)	47 M/33 F
PKU-008	Multicenter, Open-label, Extension study	Kuvan within a range of 5 to 20 mg/kg (starting at last prescribed dose in PKU-004 and at 20mg/kg from PKU-006), orally, once daily for 3 years, or until Kuvan was commercially available	PKU patients (n = 111)	16 years (4 to 50 years)	67 M/44 F

Study Results in Controlled and Open-label PKU Studies

The efficacy and safety of Kuvan were evaluated in 5 clinical studies in patients with PKU.

PKU-001 was a multicenter, open-label, uncontrolled clinical trial of 489 patients with PKU, ages 8 to 48 years (mean 22 years), who had baseline blood Phe levels ≥ 450 $\mu\text{mol/L}$ and who were not on Phe-restricted diets [4]. All patients received treatment with Kuvan 10 mg/kg/day for 8 days. For the purposes of this study, response to Kuvan treatment was defined as a $\geq 30\%$ decrease in blood Phe from baseline. At Day 8, 96 patients (20%) were identified as responders.

PKU-003 was a multicenter, double-blind, placebo-controlled study of 88 patients with PKU who responded to Kuvan in the PKU-001 study [5]. After a washout period from PKU-001, patients were randomized equally to either Kuvan 10 mg/kg/day (N=41) or placebo (N=47) for 6 weeks. Efficacy was assessed by the mean change in blood Phe level from baseline to Week 6 in the Kuvan-treated group as compared to the mean change in the placebo group.

The results showed that at baseline, the mean (\pm SD) blood Phe level was 843 (\pm 300) $\mu\text{mol/L}$ in the Kuvan-treated group and 888 (\pm 323) $\mu\text{mol/L}$ in the placebo group. At Week 6, the Kuvan-treated group had a mean (\pm SD) blood Phe level of 607 (\pm 377) $\mu\text{mol/L}$, and the placebo group had a mean blood Phe level of 891 (\pm 348) $\mu\text{mol/L}$. At Week 6, the Kuvan- and placebo-treated groups had mean changes in blood Phe level of -239 and 6 $\mu\text{mol/L}$, respectively (mean percent changes of -29% (\pm 32) and 3% (\pm 33), respectively). The difference between the groups was statistically significant ($p < 0.001$) (Table 8).

Table 8: PKU-003 Blood Phe Results


	Kuvan (N=41)	Placebo (N=47)
Baseline Blood Phe Level¹ ($\mu\text{mol/L}$)		
Mean (\pm SD)	843 (\pm 300)	888 (\pm 323)
Percentiles (25 th , 75 th)	620, 990	618, 1141
Week 6 Blood Phe Level ($\mu\text{mol/L}$)		
Mean (\pm SD)	607 (\pm 377)	891 (\pm 348)
Percentiles (25 th , 75 th)	307, 812	619, 1143
Mean Change in Blood Phe From Baseline to Week 6 ($\mu\text{mol/L}$)		
Adjusted Mean (\pm SE) ²	-239 (\pm 38)	6 (\pm 36)
Percentiles (25 th , 75 th)	-397 , -92	-96 , 93
Mean Percent Change in Blood Phe From Baseline to Week 6		
Mean (\pm SD)	-29 (\pm 32)	3 (\pm 33)
Percentiles (25 th , 75 th)	-61 , -11	-13 , 12

¹The mean baseline (BL) levels shown in this table represent the mean of 3 pretreatment levels (Wk -2, Wk-1, and Wk 0). Treatment with Kuvan or placebo started at Wk 0.

²p-value < 0.001 , adjusted mean and standard error from an ANCOVA model with change in blood Phe level from baseline to Week 6 as the response variable, and both treatment group and baseline blood Phe level as covariates.

Change in blood Phe was noted in the Kuvan-treated group at Week 1 and was sustained through Week 6 (Figure 1).

Figure 1: Mean Blood Phenylalanine (Phe) Level Over Time¹



¹Error bars indicate 95% confidence interval.

Note: Patients began Kuvan or Placebo at Week 0.

PKU-004 was a two-part, multicenter, open-label, extension study of 80 patients with PKU who responded to Kuvan treatment in study PKU-001 and completed participation in study PKU-003. In part 1, patients underwent 6 weeks of forced dose-titration with 3 consecutive 2-week courses of Kuvan at doses of 5, then 20, and then 10 mg/kg/day [6]. Blood Phe level was monitored after 2 weeks of treatment at each dose level. At baseline, mean (\pm SD) blood Phe was 844 (\pm 398) μ mol/L. Results at the end of treatment with 5, 10, and 20 mg/kg/day are presented in Table 9.

Table 9: PKU-004 Blood Phe Results From Forced Dose-Titration

Kuvan Dose Level (mg/kg/day)	No. of Patients	Mean (\pm SD) Blood Phe Level (μ mol/L)	Mean Changes (\pm SD) in Blood Phe Level From Week 0 (μ mol/L)
Baseline (No Treatment)	80	844 (\pm 398)	—
5	80	744 (\pm 384)	-100 (\pm 295)
10	80	640 (\pm 382)	-204 (\pm 303)
20	80	581 (\pm 399)	-263 (\pm 318)

In part 2, patients were assigned a fixed dose of Kuvan for 12 weeks based on their response to the 3 doses given in Part 1. Of the 80 patients in Part 2, 6 (8%) patients received 5 mg/kg/day, 37 (46%) patients received 10 mg/kg/day, and 37 (46%) patients received 20 mg/kg/day. Mean changes (\pm SD) in blood Phe levels from baseline to Week 22 were -172 (\pm 391) μ mol/L, -176 (\pm 259) μ mol/L and -209 (\pm 437) μ mol/L, respectively.

PKU-006 was a multicenter study of 90 children with PKU, ages 4 to 12 years, who were on Phe-restricted diets and who had blood Phe levels ≤ 480 $\mu\text{mol/L}$ at screening. All patients were treated with open-label Kuvan 20 mg/kg/day for 8 days in part I of the study. Response to Kuvan was defined as a $\geq 30\%$ decrease in blood Phe from baseline at Day 8 and a Phe level ≤ 300 $\mu\text{mol/L}$. At Day 8, 50 patients (56%) were considered responders to Kuvan [7]. In part 2 of the study, 45 of these PKU children, who responded to Kuvan in part 1 of the study, were then randomized 3:1 to treatment with sapropterin dihydrochloride 20 mg/kg/day (n=33) or placebo (n=12) for ten weeks. After 3 weeks of treatment, blood phenylalanine levels were significantly reduced in the Kuvan group with a mean \pm SD decrease from baseline in blood Phe level of 148 ± 134.2 $\mu\text{mol/L}$ ($p < 0.001$).

PKU-008 was a multicenter, open-label extension study of 111 patients with PKU who participated in PKU-004 or PKU-006. Doses ranged in this study between 5-20 mg/kg. The mean \pm SD exposure to sapropterin for the entire study population was 659 ± 221 days (maximum 953) and 799 ± 237 days (maximum 1151) including the previous studies. No new safety signals were seen in this extension study.

DETAILED PHARMACOLOGY

6R-BH4 (tetrahydrobiopterin) is the naturally occurring pteridine, 6R-L-erythro-5,6,7,8 tetrahydrobiopterin (6R-THBP) that is only biochemically active in the enantiomeric R form.

6R-BH4 is an endogenous cofactor for a variety of enzymes, including phenylalanine-4 hydroxylase (PAH). BH4 enhances the function of the mutated PAH enzyme, promoting oxidation of phenylalanine (Phe) to tyrosine, thus lowering blood Phe levels.

Sapropterin dihydrochloride is a synthetic formulation of 6R-BH4, developed as an oral treatment for patients with HPA resulting from PKU. Like naturally occurring BH4, formulations of sapropterin have been shown to enable endogenous PAH and to partially restore oxidative metabolism of Phe, resulting in decreased blood Phe levels in PKU patients [2] [8].

Pharmacodynamics

In PKU patients who are responsive to BH4 treatment, blood Phe levels decrease within 24 hours after a single administration of sapropterin dihydrochloride, although maximal effect on Phe level may take a month or longer, depending on the patient [2]. A single daily dose of Kuvan is adequate to maintain stable blood Phe levels over a 24-hour period. Twelve BH4 responsive patients reduced their blood Phe levels within the range of 516 to 986 $\mu\text{mol/L}$ (mean 747 ± 152.6 $\mu\text{mol/L}$), and maintained their blood Phe levels over a 24-hour period following a daily morning dose of 10 mg/kg/day. The blood Phe level remained stable during a 24-hour observation period. No substantial increases in blood Phe levels were observed following food intake throughout the 24-hour period.

Pharmacokinetics

Absorption: In animal studies, following administration of Kuvan, bioavailability is approximately 9%. In the clinical trials of Kuvan, drug was administered in the morning as a dissolved tablet without regard to meals. Studies in healthy volunteers have shown comparable absorption of sapropterin dihydrochloride when tablets are dissolved in water or orange juice and taken under fasted conditions. Administration of an intact tablet under fasted conditions resulted in an average 20% increase in C_{max} and AUC relative to dissolved tablets. Administration of a dissolved or intact tablet after a high fat/high calorie meal resulted in increases in C_{max} and AUC that ranged from approximately 30% (intact tablet AUC) to 80% (dissolved in water AUC). However, there was extensive variability in individual subject values for C_{max} and AUC across the different modes of administration and meal conditions.

Distribution: In human plasma (in vitro), the protein-binding rate remained constant (22%–34%) within the concentration range of endogenous levels (approximately 3-10 ng/mL). However, when the level exceeded 50 ng/mL, the plasma protein-binding rate decreased to 10% or lower. Erythrocyte distribution studies in rats and monkeys revealed that sapropterin distribution was saturable at whole blood concentrations exceeding 250 ng/mL.

Metabolism: Sapropterin is a dihydrochloride of 6R-BH₄, and it cannot be distinguished from endogenous 6R-BH₄ in vivo. When 6R-BH₄ is used in vivo and recycled as a cofactor in Phe metabolism, it is converted to pterin 4a-carbinolamine and then to quinoid dihydrobiopterin (R-q-DHBP) and finally reduced back to 6R-BH₄. 6R-BH₄ can be eliminated by the oxidative metabolism of dihydrobiopterin (DHBP) to biopterin (BP). In vivo, BH₄ can also be produced by a salvage pathway starting with sepiapterin which is reduced by sepiapterin reductase and dihydrofolate reductase to 6R-BH₄ [9].

Studies conducted in rats have shown that sapropterin dihydrochloride does not induce cytochrome P450 activity nor is it metabolized through the cytochrome P450 metabolic pathway.

Excretion: Sapropterin dihydrochloride and its metabolites are primarily excreted in the feces (75% of a dose) following oral administration in rats. In rats, about 7% of an orally administered dose appears in the urine within 72 hours. The mean elimination half-life in PKU patients was approximately 6.7 hours (range 3.9 to 17 h), consistent with values seen in healthy subjects. There was little evidence to suggest drug accumulation at the highest daily dose (20 mg/kg).

TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility and Developmental Effects

No evidence of carcinogenic effects was observed in mice treated orally with sapropterin dihydrochloride at doses up to 250 mg/kg/day (about the same as the human clinical dose of 20 mg/kg/day, based on body surface area) for 78 weeks; however, the treatment duration of 78 weeks is considered inadequate for a carcinogenicity study. In the 2-year rat carcinogenicity study, at oral doses of sapropterin dihydrochloride of 250 mg/kg/day (about 2 times the human clinical dose of 20 mg/kg/day, based on body surface area) there was a statistically significant increase in the incidence of benign pheochromocytomas in male rats as compared to vehicle-treated rats. A retrospective analysis of the incidence of benign pheochromocytoma in vehicle-treated animals from the same testing facility showed that the incidence observed with

sapropterin dihydrochloride in the study was not different than the historical incidence of these tumors in rats treated with vehicle.

Sapropterin dihydrochloride was noted to be weakly positive in the Ames test at concentrations of 625 µg to 5,000 µg/plate. Sapropterin dihydrochloride was positive for producing chromosomal aberrations in Chinese Hamster Lung (with and without metabolic activation) and Chinese Hamster Ovary cells (with metabolic activation), but was negative for chromosomal aberrations in human peripheral blood lymphocytes. Sapropterin dihydrochloride was not mutagenic when assessed in *in vivo* mouse micronucleus tests at doses up to 2000 mg/kg/day.

Sapropterin dihydrochloride was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg/day (about 3 times the human clinical dose of 20 mg/kg, based on body surface area).

Reproductive developmental studies have been conducted in rats and rabbits at doses up to 400 mg/kg/day and 600 mg/kg/day, respectively (about 3 times in rats and 10 times in rabbits the human clinical dose of 20 mg/kg/day, based on body surface area)

No evidence of teratogenic effects has been observed in either species; however, in rabbits there was an increase, not statistically significant, in the incidence of holoprosencephaly at the 600 mg/kg/day dose.

REFERENCES

1. Phenylketonuria (PKU): Screening and Management. NIH Consensus Statement, 2000 Oct 16-18; 17 (3): 1-33.
2. Muntau A, Roschinger W, Habich M, Demmelmair H, Hoffman B, Sommerhoff C, Roscher A. N Engl J Med. 2002; 347[26]: 2122-2132
3. Feillet F, Clarke L, Meli C, Lipson M, Morris AA, Harmatz P, et al. Pharmacokinetics of Sapropterin in Patients with Phenylketonuria. Clin Pharmacokinet. 2008; 47 (12): 817-25.
4. Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin); a phase II, multicentre, open-label, screening study. J Inher Metab Dis. 2007 Oct; 30: 700-7.
5. Levy H, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria; a phase III randomised placebo-controlled study. Lancet. 2007; 370: 504-10.
6. Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008 Nov 15; 146A: 2851-9.
7. Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009 May; 154: 700-7.
8. Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999; 135: 375-8.
9. Scriver C, Kaufman S. Hyperphenylalanemia: Phenylalanine Hydroxylase Deficiency. In: Valle, D, editor. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001: 1667-1724.

PART III: PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrKUVAN®
sapropterin dihydrochloride 100 mg Tablets

Read this carefully before you start taking **Kuvan** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Kuvan**.

What is Kuvan used for?

Kuvan is used in combination with a Phe-restricted diet to reduce blood phenylalanine (Phe) levels in patients with high blood Phe levels due to tetrahydrobiopterin (BH4)-responsive Phenylketonuria (PKU). An enzyme in your body phenylalanine hydroxylase (PAH) helps break down Phe, an amino acid found in food. This enzyme does not work right or is not present in patients with this disease. PKU can lead to high blood Phe levels in most patients. High blood Phe levels are toxic to the brain and can lead to lower intelligence and decrease in the ability to focus, remember, and organize information.

How does Kuvan work?

Kuvan activates an enzyme in the body called PAH to help reduce the blood Phe levels in some patients with PKU. The blood Phe levels must be monitored to see if Kuvan is working.

It is not possible to know whether or not Kuvan will work for you until you start taking Kuvan. Your doctor will monitor your blood Phe levels when you start taking Kuvan to see if the drug is working.

What are the ingredients in Kuvan?

Medicinal ingredients: sapropterin dihydrochloride

Non-medicinal ingredients: Ascorbic acid, crospovidone, dibasic calcium phosphate, D-mannitol, riboflavin, and sodium stearyl fumarate.

Kuvan comes in the following dosage forms:

Kuvan Tablets (100 mg) are round, mottled, off-white to light yellow and debossed with “177”.

Do not use Kuvan if:

You or your child has ever had an allergic reaction (for example a rash, or itchiness) to Kuvan or any ingredient in this medicine.

Before you take Kuvan, talk to your health care provider about any health conditions or problems you may have, including if you:

- Have a fever
- Are pregnant or planning to become pregnant
- Are breast feeding or planning to breast feed
- Have liver or kidney problems
- Are allergic to Kuvan or any ingredients in Kuvan (see “What are the ingredients in Kuvan”)
- Have burning sensation or pain in your upper abdomen/stomach
- Have too much or constant activity (such as, fidgeting, moving around too much, or talking too much)
- Have poor nutrition or have a loss of appetite
- Are taking levodopa
- Are taking drugs that inhibit folate metabolism (e.g., methotrexate) because these drugs could affect how Kuvan works in your body
- Are taking medicines for erectile dysfunction like Viagra (sildenafil), Levitra (vardenafil), or Cialis (tadalafil)

Not all patients with PKU respond to treatment with Kuvan. Your doctor will continue to monitor your blood Phe levels during your treatment with Kuvan to make sure that your blood Phe levels are not too high or too low.

Other warnings you should know about:

Kuvan should be prescribed by a doctor experienced in management of PKU. Your doctor and/or healthcare professional will regularly measure your blood Phe and provide nutritional counseling to ensure your blood Phe levels stay in the desirable range. Patients with PKU who are taking Kuvan should also be treated with a Phe-restricted diet, because high blood Phe levels with PKU can result in severe neurologic damage.

Clinical studies did not include patients aged 65 years and older. The safety and efficacy in patients less than 4 years of age have not been established in clinical trials.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Kuvan:

No drug interaction studies have been performed with Kuvan. However, the following drugs may interact with Kuvan:

- Levodopa
- Drugs that inhibit folate metabolism (e.g., methotrexate)
- Medicines for erectile dysfunction like Viagra (sildenafil), Levitra (vardenafil), or Cialis (tadalafil)

How to take Kuvan

Take Kuvan exactly as your doctor has told you.

- Take Kuvan once a day with a meal and preferably at the same time each day.
- You can swallow Kuvan whole or you can dissolve Kuvan tablets in 4 to 8 ounces (1/2 to 1 cup) of water or apple juice. You may also crush Kuvan tablets then mix in a small amount of soft foods such as apple sauce or pudding and eat within 15 minutes of mixing.
- To dissolve the tablets, mix them in water or apple juice, and drink within 15 minutes of dissolution.
 - It may take a few minutes for the tablets to dissolve. To make the tablets dissolve faster, you can stir or crush them.
 - The tablets may not dissolve completely. You may see pieces floating on top of the water or apple juice. This is normal and safe for you to swallow.
 - If after drinking your medicine you still see pieces of the tablet, you should add more water or apple juice to make sure that you take all of your medicine.

When you are taking Kuvan, any change you make to your diet may affect your blood Phe level. Follow your doctor's instructions carefully and do not make any changes to your dietary Phe intake before discussing with your doctor. Your doctor will continue to monitor your blood Phe levels during your treatment with Kuvan to make sure that your blood Phe levels are not too high or too low.

If you have a fever, or if you are sick, your blood Phe level may go up. Tell your doctor as soon as possible so they can change your dose of Kuvan to help keep your blood Phe levels in the desired range.

Usual Dose:

- Kuvan starting dose: 10 mg/kg body weight taken once daily with a meal
- Your doctor can change your dose of Kuvan depending on how you respond to treatment.

Overdose:

Patients who have accidentally taken too much Kuvan, reported mild headache, mild dizziness, and/or too much or constant activity (hyperactivity).

If you think you have taken too much Kuvan, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you forget to take your dose of Kuvan, take it as soon as you remember that day. But if you miss the dose for that day, skip the missed dose, and continue with your scheduled dose the following day. Do not take two doses of Kuvan on the same day.

What are possible side effects from using Kuvan?

These are not all the possible side effects you may feel when taking Kuvan. If you experience any side effects not listed here, contact your healthcare professional. Please also see Warnings and Precautions.

The most common side effects reported when using Kuvan are:

- Headache
- Runny nose and stuffy nose
- Diarrhoea
- Stomach or belly pain
- Upper respiratory tract infection (like a cold)
- Throat pain
- Vomiting
- Nausea

Be sure to tell your doctor if you have any side effects when you are taking Kuvan.

Serious side effects and what to do about them				
Symptom / effect		Talk to your healthcare professional		Stop taking drug and get immediate medical help
		Only if severe	In all cases	
COMMON	Cough	√		
	Throat pain	√		
UNCOMMON	Fluid accumulation beneath skin of lower limbs	√		
	Hives (itchy bumpy rash)	√		
	Severe allergic reactions called anaphylaxis (signs of anaphylaxis include heavy breathing with whistling sound, trouble breathing, coughing, feeling dizzy or faint, turning red, nausea, and rash.)		√	√
	Oesophageal (foodpipe) disorder	√		
	Pale skin	√		
	Retching (gagging)	√		
	Shortness of Breath	√		
	Swelling of Eyelid	√		
	Throat tightness			√

RARE	Burning sensation or pain in your upper abdomen/stomach		√	
-------------	--	--	---	--

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at [MedEffect](#);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 0701E
Ottawa, ON
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](#).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store in a cool, dry place between 20°C -25°C; excursions allowed between 15°C - 30°C.
- Do not leave Kuvan in hot or humid places, such as your car or bathroom cabinet.
- Keep Kuvan in its original bottle with the cap closed tightly.
- Protect from moisture. Do not remove the desiccant (the small packet included with your tablets). The desiccant absorbs moisture.
- The color of the tablets may change over time, to yellow. This is normal and you can take these tablets.
- Do not keep Kuvan that is out of date, or that you no longer need. Be sure that if you throw any medicine away, it is out of the reach of children.

Keep out of reach and sight of children.

If you want more information about Kuvan:

- Talk to your healthcare professional

- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](#); or by calling 1-877-597-6744.

This leaflet was prepared by BioMarin Pharmaceutical (Canada) Inc.

Last Revised: December 4, 2014